The global atopic dermatitis (AD) population is around 223 million with a prevalence rate up to 15% in children, and studies have shown that the global population of AD is increasing. According to the market analysis report of Grand view research, the global market size for atopic dermatitis drugs was valued at USD 15.76 billion in 2023, and it is estimated to reach USD 27.72 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The topical drug segment accounted for around 25% of market share by route of adminstration in 2022 (Grand view research 2023). The US is the largest market and accounted for 75% of the global sales for AD drugs, followed by Europe and Japan (Global Data 2020).